Best Peptides for Anxiety and Stress Research

By NorthPeptide Research Team · April 8, 2026

Why Peptide Research in Anxiety and Stress Is Growing

Anxiety disorders are among the most prevalent neurological conditions globally, affecting an estimated 284 million people worldwide according to the Global Burden of Disease study. Current pharmacological approaches — primarily SSRIs, SNRIs, and benzodiazepines — are effective for many patients but carry significant limitations: SSRIs require weeks to reach therapeutic effect, benzodiazepines carry dependence and cognitive impairment risks, and a substantial minority of patients show inadequate response to available treatments.

Research interest in peptides for anxiety and stress biology stems from several converging observations. First, the brain has its own endogenous peptide signaling systems for modulating stress and anxiety — including neuropeptide Y, enkephalins, and CRH-related peptides — suggesting that peptide-based approaches may work more compatibly with the brain’s native chemistry than small-molecule drugs that target single receptor types. Second, peptides like Selank and Semax have demonstrated anxiolytic properties in controlled research settings with mechanisms of action distinct from benzodiazepines, raising the possibility of efficacy without the same side effect profile. Third, emerging research on neuroinflammation as a contributor to anxiety disorders has opened a new mechanistic avenue for peptides with anti-inflammatory properties.

This guide covers five peptides with distinct mechanisms that researchers have studied in the context of stress and anxiety biology.

Selank: GABAergic Modulation and Enkephalin Stabilization

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed from the immunomodulatory peptide tuftsin at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has been an approved pharmaceutical product in Russia since 2009, marketed as a 0.15% nasal spray for generalized anxiety disorder and neurasthenia. This regulatory approval, based on controlled clinical trials conducted through the Russian pharmaceutical registration process, makes Selank one of the few research peptides in this category with a genuine clinical development history.

Selank’s anxiolytic mechanism involves multiple interconnected pathways:

• GABAergic modulation: Selank has been shown to allosterically modulate GABA-A receptors, enhancing inhibitory GABAergic neurotransmission without directly binding to the benzodiazepine site. This benzodiazepine-like mechanism without benzodiazepine-site binding is pharmacologically significant because the benzodiazepine site is associated with the sedation, tolerance, and dependence that limit long-term benzodiazepine use.
• Enkephalin stabilization: Selank inhibits the aminopeptidases responsible for degrading enkephalins — the brain’s endogenous opioid peptides involved in stress response and mood regulation. By extending the active lifespan of leu-enkephalin and met-enkephalin at the synapse, Selank may enhance the natural stress-buffering capacity of the endogenous opioid system.
• Serotonin metabolism modulation: Research has documented that Selank influences serotonin turnover in the hypothalamus, hippocampus, and frontal cortex — brain regions central to anxiety and mood regulation. (Semenova et al., Eksperimental’naia i klinicheskaia farmakologiia 2001)
• BDNF and NGF expression: Selank has been shown to upregulate BDNF in the hippocampus, though the magnitude appears smaller than that produced by Semax. BDNF is a critical regulator of neuroplasticity and has been implicated in the pathophysiology of anxiety disorders.
• Immune modulation: As a tuftsin analog, Selank retains immunomodulatory properties including effects on interleukin-6 and interferon production. Given the growing research interest in the relationship between immune dysregulation and anxiety, this dual profile makes Selank uniquely positioned for research into anxiety-inflammation relationships.

Controlled clinical trials conducted in Russia evaluated Selank in patients with generalized anxiety disorder and found anxiolytic effects comparable to medazepam (a benzodiazepine) without the sedative or amnestic effects characteristic of benzodiazepines. (Zozulya et al., Bull Exp Biol Med 2001)

Semax: BDNF Upregulation and Stress Resilience

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the ACTH(4-7) fragment, with a Pro-Gly-Pro C-terminal extension for metabolic stability. Also developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has been approved in Russia and several CIS countries since 1996 for cognitive enhancement and stroke recovery. While primarily researched as a nootropic, its mechanisms have direct relevance to stress and anxiety biology.

The primary mechanisms with relevance to stress and anxiety include:

• BDNF upregulation: Semax consistently and potently upregulates brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex. A 2010 study documented a 1.4 to 1.8-fold increase in hippocampal BDNF mRNA following Semax administration in rats. (Dolotov et al., Neuroscience Letters 2010) BDNF plays a critical role in hippocampal neurogenesis, which is disrupted by chronic stress and has been proposed as a mechanism through which chronic stress produces anxiety-like states.
• MC4R agonism: Semax acts at melanocortin 4 receptors (MC4R) in the hippocampus and prefrontal cortex. MC4R activation has been associated with enhanced synaptic plasticity and stress resilience in animal models.
• Dopamine and serotonin modulation: Research has documented that Semax influences dopamine and serotonin turnover in the striatum and nucleus accumbens. Disruptions in these neurotransmitter systems are central to the pathophysiology of both anxiety and depression.
• HPA axis modulation: Some research has examined Semax’s effects on stress hormone systems. Studies in rodents have reported attenuated corticosterone responses to stressors following Semax administration, suggesting potential effects on hypothalamic-pituitary-adrenal (HPA) axis reactivity.

Where Selank is more specifically anxiolytic (acting more directly on the anxiety substrate through GABAergic and enkephalinergic mechanisms), Semax appears to work more through enhancing neuroplasticity and resilience — a somewhat different mechanistic angle that may make the two compounds complementary in research contexts examining different aspects of stress biology.

DSIP: Delta Sleep-Inducing Peptide and the Stress-Sleep Connection

Delta sleep-inducing peptide (DSIP) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit thalamus in 1977 by Monnier and colleagues. It was named for its initial finding that it could induce delta-wave sleep when administered to rabbits — a property that has made it one of the most studied neuropeptides in sleep research, though the study of its broader stress regulatory effects has grown considerably since.

The mechanistic relationship between DSIP and stress biology is multi-layered:

• CRH and ACTH modulation: DSIP has been shown to inhibit corticotropin-releasing hormone (CRH) secretion and modulate adrenocorticotropic hormone (ACTH) release from the pituitary. Since CRH is a central mediator of the stress response — it is released from the hypothalamus in response to stressors and initiates the HPA axis cascade — DSIP’s effects on CRH signaling represent a direct mechanism through which it could influence stress biology. (Graf & Schoenenberger, Eur J Pharmacol 1983)
• Sleep architecture normalization: Chronic stress disrupts sleep architecture, and disrupted sleep worsens stress reactivity — a well-documented bidirectional relationship. DSIP’s effects on delta sleep may partially explain its stress regulatory properties: by improving sleep quality, it may help restore the neuroendocrine recovery processes that occur during deep sleep.
• Antioxidant effects: Research has documented antioxidant properties for DSIP, including reduction of lipid peroxidation in brain tissue. Oxidative stress is increasingly recognized as a contributor to anxiety-related neurological changes.
• Anti-epileptic and anticonvulsant properties: DSIP has shown anticonvulsant effects in animal models, suggesting modulation of neuronal excitability that may relate to its anxiolytic-adjacent effects.

The research history of DSIP spans nearly five decades and dozens of published studies, making it one of the more extensively investigated neuropeptides in this category despite remaining outside mainstream pharmaceutical development. (Yehuda & Mostofsky, 1991 review)

KPV: Neuroinflammation and the Anxiety-Inflammation Axis

KPV is a tripeptide (Lys-Pro-Val) representing the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). While its research profile is best established in the context of gut inflammation and wound healing, emerging research on neuroinflammation as a contributor to anxiety disorders has brought KPV into focus in neurological contexts.

The mechanistic rationale for researching KPV in anxiety biology rests on several converging lines of evidence:

• MC1R agonism: KPV acts as an agonist at melanocortin 1 receptors (MC1R), which are expressed not only in skin (where they regulate melanin production) but also in microglia — the resident immune cells of the brain. Microglial MC1R activation produces anti-inflammatory effects, reducing the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6.
• NF-κB inhibition: KPV has been shown to inhibit NF-κB, a master transcription factor for inflammatory gene expression, in multiple cell types. In neuroinflammatory contexts, NF-κB inhibition would be expected to reduce cytokine-mediated disruption of neurotransmitter systems.
• Gut-brain axis: KPV’s well-documented anti-inflammatory effects in intestinal epithelial cells are relevant because gut inflammation and intestinal barrier dysfunction are increasingly linked to neuroinflammation through the gut-brain axis. The gut microbiome influences brain chemistry through this axis, and compounds that reduce gut inflammation may secondarily affect brain inflammatory status.
• Cytokine-anxiety relationship: Multiple clinical and preclinical studies have found associations between elevated pro-inflammatory cytokines (particularly IL-6 and TNF-α) and anxiety symptoms. If neuroinflammation is a driver of anxiety in a subset of individuals, anti-inflammatory peptides like KPV could represent a mechanistically appropriate intervention to study.

It is important to note that KPV’s research in explicitly anxiety-relevant contexts is less developed than Selank or Semax — it is more accurately characterized as a peptide with mechanisms relevant to neuroinflammation that has research implications for anxiety, rather than a directly studied anxiolytic. This mechanistic positioning makes it interesting for researchers investigating the inflammatory hypothesis of anxiety disorders.

Pinealon: Pineal Bioregulator and Circadian Stress Modulation

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It belongs to the family of short regulatory peptides (cytomedins) pioneered by Vladimir Khavinson and colleagues, which are designed to act as gene-activating sequences — short peptides that penetrate cell membranes and directly bind to gene promoter regions.

Unlike the other peptides in this guide, Pinealon’s primary research focus is the pineal gland and its products, particularly melatonin. The pineal gland is the primary biological clock of the mammalian brain, and its output of melatonin orchestrates circadian rhythms including the sleep-wake cycle, neuroendocrine rhythms, and immune function cycles. Disruption of circadian rhythms — common in shift workers, travelers, and individuals under chronic stress — is strongly associated with increased anxiety and mood disorders.

Pinealon’s research profile includes:

• Pinealocyte gene activation: Pinealon has been shown to penetrate pinealocyte (pineal gland cell) nuclei and activate the expression of genes involved in pineal function, including those related to melatonin synthesis. Published research from the Khavinson group documented nuclear penetration and gene expression effects in cell culture studies. (Khavinson et al., Neuro Endocrinol Lett 2012)
• Melatonin pathway effects: Studies in aged animals have documented that Pinealon administration is associated with normalization of melatonin secretion rhythms — suggesting a potential role in restoring circadian disruption associated with aging or chronic stress.
• Antioxidant properties: Like melatonin itself, Pinealon has demonstrated antioxidant activity in research models, which is relevant given the role of oxidative stress in age-related neurological decline.
• Neuroprotective effects: Research has examined Pinealon’s effects in models of ischemic brain injury, where it appears to reduce neuronal apoptosis. This neuroprotective profile is mechanistically consistent with the broader peptide bioregulator literature.

Pinealon’s place in anxiety and stress research is most accurately framed as circadian and neuroendocrine. Stress disrupts circadian rhythms, disrupted circadian rhythms worsen stress sensitivity, and restoring pineal function may support the natural rhythmic recovery processes that healthy sleep enables. This makes Pinealon particularly interesting for researchers studying shift work, jet lag, or stress models involving circadian disruption.

Comparison: Mechanisms and Research Positioning

Research Considerations

For researchers designing studies in anxiety and stress biology using research peptides, several considerations apply:

Mechanism selection matters: These five peptides operate through genuinely distinct mechanisms. A study examining GABAergic modulation would most appropriately use Selank; one examining neuroinflammation would use KPV; one examining circadian stress would use Pinealon or DSIP. Selecting compounds based on mechanistic alignment with the research question — rather than assumed general anxiolytic properties — produces more interpretable results.

Animal model choice: Most of the published research on these peptides uses rodent models (rats and mice). The translational validity of anxiety models in rodents — particularly common paradigms like the elevated plus maze, forced swim test, and open field test — is an ongoing methodological discussion in the field. Researchers should consider which animal model best captures the aspect of anxiety biology they are investigating.

Intranasal administration specifics: For Selank and Semax, which are designed for intranasal administration, the route affects both pharmacokinetics and potential direct nose-to-brain transport. Researchers using subcutaneous administration protocols should be aware that they may observe different dose-response relationships than those reported in intranasal studies.

Complementary mechanisms: Because these peptides act through distinct pathways, they are potentially complementary rather than redundant. Combination research designs examining, for example, Selank (GABAergic mechanism) paired with DSIP (HPA axis mechanism) could address multi-system models of anxiety biology in ways that single-compound studies cannot.